[go: up one dir, main page]

AR122300A1 - Formulaciones proliposomales de testosterona undecanoato - Google Patents

Formulaciones proliposomales de testosterona undecanoato

Info

Publication number
AR122300A1
AR122300A1 ARP200102272A ARP200102272A AR122300A1 AR 122300 A1 AR122300 A1 AR 122300A1 AR P200102272 A ARP200102272 A AR P200102272A AR P200102272 A ARP200102272 A AR P200102272A AR 122300 A1 AR122300 A1 AR 122300A1
Authority
AR
Argentina
Prior art keywords
weight
testosterone undecanoate
ratio
proliposomal
proliposomal powder
Prior art date
Application number
ARP200102272A
Other languages
English (en)
Inventor
Veeran Gowda Kadajji
Natarajan Venkatesan
Nitin K Swarnakar
Teresa Hong
Ramachandran Thirucote
Guru V Betageri
Original Assignee
Tesorxpharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesorxpharma Llc filed Critical Tesorxpharma Llc
Publication of AR122300A1 publication Critical patent/AR122300A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere a dispersiones de polvo proliposomales de testosterona undecanoato (TU) y fosfolípidos, que incluye dispersiones de TU y palmitoilfosfatidilcolina (DPPC), donde la relación peso/peso (p/p) de TU:DPPC en la dispersión de polvo proliposomal es aproximadamente 1:2; o TU y 1,2-dimiristoil-sn-glicero-3-fosfocolina (DMPC), donde la relación peso/peso (p/p) de TU:DMPC en la dispersión de polvo proliposomal es aproximadamente 1:3; o TU y 1-miristoil-2-palmitoil-sn-glicero 3-fosfocolina (MPPC), donde la relación peso/peso (p/p) de TU:MPPC en la dispersión de polvo proliposomal es aproximadamente 1:3.
ARP200102272A 2019-08-09 2020-08-10 Formulaciones proliposomales de testosterona undecanoato AR122300A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962884919P 2019-08-09 2019-08-09

Publications (1)

Publication Number Publication Date
AR122300A1 true AR122300A1 (es) 2022-08-31

Family

ID=74569809

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102272A AR122300A1 (es) 2019-08-09 2020-08-10 Formulaciones proliposomales de testosterona undecanoato

Country Status (13)

Country Link
US (1) US20220265679A1 (es)
EP (1) EP4009950A4 (es)
JP (1) JP2022544197A (es)
KR (1) KR20220054318A (es)
CN (1) CN114667133B (es)
AR (1) AR122300A1 (es)
AU (1) AU2020329775A1 (es)
BR (1) BR112022002418A2 (es)
CA (1) CA3146515A1 (es)
IL (1) IL290464A (es)
MX (1) MX2022001417A (es)
TW (1) TWI867026B (es)
WO (1) WO2021030260A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US20120135074A1 (en) * 2010-11-30 2012-05-31 Chandrashekar Giliyar High-Strength Testosterone Undecanoate Compositions
SG10201702240TA (en) 2012-05-09 2017-05-30 Univ Western Health Sciences Proliposomal testosterone formulations
US20140271822A1 (en) * 2013-03-13 2014-09-18 Mallinckrodt Llc Modified docetaxel liposome formulations
DK3400072T3 (da) 2016-01-07 2021-03-22 Tesorx Pharma Llc Formuleringer til behandling af blærecancer
EP3399965A4 (en) * 2016-01-08 2019-08-21 Western University Of Health Sciences PROLIPOSOMAL TESTOSTERONE ANDECANOATE FORMULATIONS
EP3538074B1 (en) * 2016-11-11 2023-07-26 Western University Of Health Sciences Methods of treating upper tract urothelial carcinomas

Also Published As

Publication number Publication date
TW202216162A (zh) 2022-05-01
EP4009950A4 (en) 2023-07-05
IL290464A (en) 2022-04-01
EP4009950A1 (en) 2022-06-15
WO2021030260A1 (en) 2021-02-18
CN114667133A (zh) 2022-06-24
BR112022002418A2 (pt) 2022-06-14
CA3146515A1 (en) 2021-02-18
JP2022544197A (ja) 2022-10-17
AU2020329775A1 (en) 2022-02-24
MX2022001417A (es) 2022-06-08
TWI867026B (zh) 2024-12-21
CN114667133B (zh) 2025-01-14
US20220265679A1 (en) 2022-08-25
KR20220054318A (ko) 2022-05-02

Similar Documents

Publication Publication Date Title
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
BR112017003419A2 (pt) formulação de anticorpo anti-il-4r-alfa estável
CL2020001312A1 (es) Composiciones de cannabidiol y usos de las mismas. (divisional solicitud 201803425).
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
CL2018003604A1 (es) Composiciones farmacéuticas para terapia combinada (divisional solicitud 201701983)
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
CO2020001242A2 (es) Dihidrooxadiazinonas
MX2022002633A (es) Mimeticos de hepcidina conjugada.
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
UY40003A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
BR112016018283A2 (pt) Composição que compreende bifidobacterium animalis ssp. lactis
CL2021003266A1 (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
CL2020003133A1 (es) Formulación para uso en el tratamiento simultáneo de infecciones provocadas por coccidios y deficiencias de hierro
CL2022002833A1 (es) Anticuerpos anti-flt3 y composiciones
MX2021004566A (es) Compuestos terapeuticos.
DOP2021000081A (es) Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.
MX2018000021A (es) Composiciones multifasicas.
MX2018012671A (es) Combinacion, usos terapeuticos y usos profilacticos.
AR122300A1 (es) Formulaciones proliposomales de testosterona undecanoato
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
BR112023024034A2 (pt) Polipeptídeos de sars-cov-2
UY29417A1 (es) Agentes endoparasiticidas
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
BR112022006643A2 (pt) Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas